Ubiquitination plays a pivotal role in most cellular processes and is critical for protein degradation and signalling. E3 ligases are the matchmakers in the ubiquitination cascade, responsible for substrate recognition and modification with specific polyubiquitin chains. Until recently, it was not clear how the catalytic activity of E3s is modulated, but major recent studies on HECT E3 ligases is filling this void. These enzymes appear to be held in a closed, inactive conformation, which is relieved by biochemical manoeuvres unique to each member, thus ensuring exquisite regulation and specificity of the enzymes. The new advances and their significance to the function of HECT E3s are described here, with a particular focus on the Nedd4 family members.
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The ubiquitin (Ub) pathway regulates many biological processes and determines how cells respond to growth factors, stress and genetic damage, controlling nearly every facet of a cell's life and death. The importance of Ub in physiology and in medicine has greatly evolved during the past two decades thanks to the molecular dissection of various ubiquitin-mediated protein degradation pathways that occur at dedicated organelles, namely the proteasome, the lysosome and the autophagosome.
Despite the explosion of functional studies, nicely reviewed elsewhere [1] [2] [3] [4] [5] [6] , numerous mysteries in the biochemistry behind the ubiquitination process remain unsolved. Here, we focus on some of the crucial questions that were recently unravelled by studying HECT E3 ligases. Indeed, structural and biochemical studies have started to shed light on the molecular determinants of catalysis, the way the enzymes are kept inactive and are subsequently activated and how they extend ubiquitin chains to achieve linkage-specific polyubiquitination. We also discuss the emerging theme of inhibitors and probes for the NEDD4 family members, which represent attractive potential therapeutic targets.
E3 ligases -an overview
Finding the right target is a crucial step in the ubiquitination process, in which the ligases (E3s) play a fundamental role as molecular matchmakers capable of conferring a high degree of specificity towards substrates and the ubiquitin chain linkage built on them Abbreviations DUB, deubiquitinating; GEF, guanine nucleotide-exchange factor; HECT, homologous to E6-AP carboxyl terminus; RBR, ring between ring; RCC, regulator of chromosome condensation; RING, really interesting new gene; RLD, regulator of chromosome condensation 1-like domain. [7, 8] . E3 ligases are classified into three classes: really interesting new gene (RING), homologous to E6-AP carboxyl terminus (HECT) and ring between ring (RBR). Each class of E3s is characterized by conserved functional and structural features. The majority of the 600 E3s present in humans belong to the RING family, which are characterized by a cross-brace structure with two zinc ions coordinated by cysteine and histidine residues. The RING family catalyses ubiquitin transfer, functioning as a molecular scaffold for the E2 and the substrate and priming the ubiquitin on the E2 enzyme for the nucleophilic attack of the substrate lysine [8] . HECT E3s are defined by a 350 residues module, first characterized in the human E3 ligase E6-associated protein E6AP [9] , invariably positioned at the C-terminal. Differently from the RING, the enzymatic activity of HECT occurs in two steps: first, with a transthiolation reaction between the E2 and the E3, the Ub is transferred to the cysteine on the active site of the HECT domain. In the second step, the Ub moiety is transferred from the HECT intermediate to a lysine on the target substrate. The RBRs, that count 14 members in humans, show characteristics of both RING and HECT-type E3s since they possess two RING domains, one that acts as a scaffold and another that contains a cysteine involved in the formation of the catalytic intermediate [10] .
Structural features of HECT E3 ligases
In mammals, there are 28 HECT enzymes that are further divided into three subgroups according to their protein-protein interaction domain architecture: HECT E3s with C2 and several WW domains (termed Nedd4/ Nedd4-like E3s), HECTs with RLDs (RCC1-like domains) that are called HERC (HECT and RCC1-like domain), and HECTs that neither contain C2, RLDs nor WW domains. The Nedd4 family, which comprises nine members in humans that share common domain architecture with unique functional properties, is the most intensively studied family of E3 ligases [5, 11, 12] . Starting from the N-terminus, they present a C2 domain responsible for the regulation of cellular localization and two-to-four WW domains in charge of substrate selection. Both regions could also be involved in a regulatory intramolecular interaction with the C-terminal HECT domain.
The C2 domain is a~130 residues module, folded in an eight-stranded b-sandwich structure and originally described as a Ca 2+ -dependent phospholipid binding domain of the protein kinase C [13] . Since its discovery, a wide variety of carrying proteins have been identified, pointing to a great functional diversity of this domain. Indeed, the C2 domain may bind calcium, phospholipids, inositol phosphate but also proteins and has different binding affinities according to each domain [14] .
The WW domain contains two conserved tryptophan residues that are spaced 20-22 amino acids apart, hence the name 'WW domain'. This domain is a compact module folded in three stranded antiparallel beta-sheets forming a hydrophobic ligand-binding groove [15, 16] often present in multiples copies within the same protein. It is found in a variety of unrelated proteins (e.g. dystrophin, Pin1, YAP65), and has a key role in mediating protein-protein interaction via recognition of proline-rich motifs and phosphorylated serine/threonine-proline sites. WW domains are classified into four classes according to the sequence motifs they recognize [17, 18] . In Nedd4 E3s, WW domains are fundamental for substrate recognition. These ligases bear class I type domains, able to bind PY motifs (L/PPxY). Notably, WW domains from the same E3 may function independently and can have distinct binding preferences [19] . Thus, the WW-rich region in NEDD4 family members serves as a scaffold to recruit proteins and regulators, and provides these enzymes with a versatile platform that remains to be fully characterized.
The second family of HECT proteins is the HERC family and counts six members in humans [5, 12] . Based on their size and domain architecture, the family is subdivided into large HERCs (HERC1-2) and small HERCs (HERC3-6). While the small proteins have a molecular mass of approximately 120 kDa and contain little more than the HECT and RLD domains, the large HERCs are giant proteins with a molecular weight of more than 500 kDa and possess more than one RLD and several other conserved regions. The defining structural element of this class is the regulator of chromosome condensation 1 (RCC)-like domain (RLD). Structurally, the RLD is characterized by the presence of several (usually seven) repeats of 51-68 amino acids each that adopt a seven-bladed b-propeller fold. Functionally, the RLD domain has a double role: one surface acts as a guanine nucleotide-exchange factor (GEF) for the small GTPase Ran, while the opposite side interacts with chromatin through histones H2A and H2AB.
The remaining HECT proteins either show no additional structural domains (E6AP, HECTD1 and HECTD4) or carry various domains in their N-terminal extension. Among them, HUWE1 and TRIP12 contain a WWE domain, HACE1 and the related HECTD1 contain ankyrin repeats, and UBE3B and UBE3C carry an IQ.
Structural basis of HECT catalysis
The defining structural element of HECT ligases is the conserved HECT domain that is both necessary and sufficient for catalysis. This domain has a bilobed structure with a bigger N-terminal lobe (N-lobe) that contains the E2 binding site, and a smaller C-terminal lobe (C-lobe) carrying the catalytic cysteine involved in the ubiquitin transfer [20] . The two lobes are connected by a flexible hinge region that permits the C-lobe to span virtually 360°around the hinge, as underlined by the different conformations adopted in the solved structures of the HECT domains. An early study has reported that restriction of the relative movements of the lobes inhibits self-ubiquitination reactions [21] . Crystal structures capturing the binding of the HECT with the Ub-loaded E2 [22] and the moment immediately after the transthiolation process have shown that the free movement of the hinge loop is fundamental for the juxtaposition of the cysteine residues of the E2 and the E3 during the Ub transfer. These studies have also highlighted a critical interaction occurring between the donor Ub (Ub D ) and the C-lobe. This binding has two functions; when Ub is loaded on the E2, it helps to position the Ub in order to favour the transthiolation process between the two catalytic cysteines [22] . When Ub is loaded on the HECT, it locks the C-terminal tail of Ub in an extended conformation, primed for catalysis [23] . Interestingly, binding of RING E3s to a thioester-linked E2 Ub promotes a 'folding back' of Ub against E2 (called 'closed' conformation) that stretches the Ub in a similar manner and allosterically activates discharge of intermediates [24] [25] [26] [27] [28] [29] [30] [31] . Thus, docking the flexible C-terminal tail of Ub in an extended conformation appears to be a common, evolutionary-conserved mechanism adopted by both E2s and E3s to prime the Ub D for catalytic transfer to the substrate, although exceptions of this rule are possible for some RBRs [32] .
The biochemical data accompanying the first crystal structure of an active HECT [23] provided also important insights into the residues responsible for the final step of the HECT catalysis, namely substrate ubiquitination. Indeed, Maspero et al. [23] identified a strictly conserved C-terminal acid residue that is essential for substrate ubiquitination but dispensable for the E2-E3 transthiolation. As suggested in [10] , this aspartate (D900 in NEDD4) together with the histidine in close proximity to the catalytic cysteine (H865 and C867 in NEDD4) may indicate the existence of a catalytic triad similar to the one present in parkin and HHARI (residues C431A, H433A, E444A in parkin). Indeed, all three residues are evolutionarily conserved in NEDD4 family members. The C-terminal acid residue can contribute to the formation of the active catalytic site, as well as help to position the acceptor Ub (Ub   A   ) . Indeed, the C terminus of HECT E3 ligases has an important role in determining chain specificity as substitution of the last three NEDD4 amino acids with the E6AP sequence (not a NEDD4 family member) changes the specificity of the ubiquitin-chain product from pure K63-linked chains to a mixture of K48-and K63-linked chains [23] . The definitive role of the C terminus of HECT E3s remains, however, to be determined as these final residues are either disordered [23] or mediate crystal contacts [33] in the existing structures.
The process of substrate ubiquitination was further illuminated by the crystal structure of the Ub-loaded Rsp5 in complex with Sna3 substrate peptide obtained with a three-way chemical crosslinker [33] . This structure provided for the first time, hints about the wellknown phenylalanine in position -4/-5 that is required for catalysis [34] . Elegant mutational analysis defined that its role is to mediate the interlobe contacts creating the active site and keeping them in an orientation suitable for substrate ubiquitination [33] . It is noteworthy that in this structure the C-lobe undergoes a 130 o rotation around the hinge relative to the conformation of the HECT-Ub primed for catalysis [23] . The combined data further confirm the need of a flexible hinge and the idea that NEDD4 functions as if in a relay (Fig. 1) . First, NEDD4 faces E2 to receive ubiquitin (the baton). Then, the NEDD4 HECT E3 turns around to face the substrate and passes the baton to it. Whether this mechanism holds true for the remaining steps, i.e. polyubiquitin chain elongation, remains to be demonstrated. An intriguing possibility is that once few ubiquitins are attached to the substrate, the C-lobe may not require this long turn and remains in a conformation more closed to the one of the transthiolation process (Fig. 1) . The presence of a noncovalent Ub-binding site on the N-lobe, distal from the Ub-binding site on the C-lobe, in several members of the NEDD4 family supports this idea [35] [36] [37] [38] . Disruption of the Ub:N-lobe interaction impairs chain elongation but not conjugation of the first ubiquitin to a substrate [37] . Further characterization in Rsp5 and human Nedd4, Nedd4L and WWP1 confirmed that this exosite is required for processivity and promotes chain elongation, possibly by stabilizing and orienting the distal end of growing Ub chains on the substrate [23, [37] [38] [39] .
Selecting the correct ubiquitin linkage
Various types of ubiquitination signals exist in all eukaryotic cells. They are specifically decoded and target the modified proteins for different fates [40, 41] .
In a polyubiquitin chain, ubiquitin molecules can be linked through one of the seven ubiquitin lysine residues (K6, K11, K27, K29, K33, K48 and K63) or through the ubiquitin amino terminal methionine residue [39] . The ability to build linkage-specific Ub chains is an intrinsic feature of the HECT domains, independently from the E2 they are coupled with [42] . Different HECT E3s display distinct Ub chain specificity and the exact mechanisms through which they assemble these polyubiquitin chains remain poorly defined.
The best-studied examples are the members of the NEDD4 family that catalyse K63 linkages [23, 38, 43] through a sequential addition mechanism in which a single Ub molecule is added one at time to the growing polyUb chain [23, 38, 44] . Pioneering work from Huibregtse and colleagues demonstrated that substitution of the last 60 amino acids of the C-lobe of Rsp5 with the ones of E6AP C-lobe alters the chain specificity towards K48, indicating that the C-terminal part of the C-lobe of the HECT domain possesses all the critical features for chain type specificity [38] . This surface not only overlaps with the Ub D binding site, but also covers an extra region that may well be the Ub A binding site, responsible for the correct positioning of the attacking lysine (Fig. 2) . This hypothesis combined with the data showing that the exosite present in the N-lobe is required for chain elongation [23, 37, 38] led us to propose a model whereby the Cterminal 60 amino acids of the C-lobe are capable of arranging both Ub D and Ub A (Fig. 2) . This structural conformation guides the K63 of the Ub A into the active site and determines the exquisite chain specificity of this HECT family. This model predicts the existence of a sliding mechanism to liberate the Clobe once the conjugation of the Ub D to the growing chain is achieved. All these hypotheses await experimental validation.
NEDD4 family members are able to generate K63-linked chains in vitro but several reports highlighted the fact that NEDD4 substrates are targeted for HECT N-lobe in blue, HECT C-lobe in green, Ub in yellow, E2 in red, WW domains in orange and substrate in pink. The model depicts the different conformations that the HECT enzyme may assume. First, the HECT C-lobe engages the Ub loaded onto the E2, allowing transthiolation. Then, the C-lobe~Ub turns around the hinge region in order to face the substrate and transfer the Ub to it. Once the isopeptide bond has been formed, the C-lobe switches back to accept Ub from a second E2~Ub. The C-lobe rotates then again towards the substrate and generates Ub dimer. In the following ubiquitination cycles, the N-lobe exosite (depicted as yellow dashed circle on the N-lobe) may help to maintain the growing Ub chain in close proximity and positions the Ub acceptor (Ub A ) in the correct orientation. This limits the C-lobe rotation, favouring enzyme processivity.
proteasome-mediated degradation [44] [45] [46] [47] [48] . How can K63 polyUb and proteasome degradation be considered products of the same enzymatic activity? In vivo, several explanations are plausible. Specific adaptors may alter the orientation of the Ub A or Ub D . Alternatively, a deubiquitinating (DUB) enzyme may team up with the HECT enzyme to edit substrates, as was shown for the yeast orthologue of the NEDD4 family, Rsp5 that mediates cytosolic protein degradation under stress conditions [48] . Upon heat stress, Ubp2 and Ubp3 deubiquitinases associate more with Rsp5 to prevent the assembly of K63-linked ubiquitin chains on Rsp5 substrates [49] . K63-modified substrates might also be recognized by other E3 ligases -yet to be discovered -that subsequently modify the chains, like in the case of SUMO-targeted ubiquitin ligase (STUbL) family proteins [50] . Recently, French et al. [35] provided a simpler explanation, suggesting that, at least for WWP1, chain synthesis works in two different phases; a more stringent initial phase that results in K63-specific Ub tetramers and one less defined phase in which chains are elongated via different lysines. The longer, branched structures created are well recognized by the proteasome [35] . It should be mentioned that NEDD4 can generate K11 linkages (even if at lower efficiency), and substrates modified in this way are targeted for degradation [51] .
Less is known about the other HECT ligases. Initial results obtained with UBE3C (former KIAA10 also termed RAUL) and E6AP (also called UBE3A) suggested that these enzymes may adopt a mechanism different from the sequential addition mechanism in place for the NEDD4 family [52] . More recent studies indicate that an E6AP oligomer is the catalytically competent form of the enzyme [53] , although this finding has been challenged [54] . Certainly, E6AP and Huwe1 are considered K48-type of E3 ligases [38, 52, 55, 56] and do not appear to carry ubiquitin binding surface in the HECT domain such as the exosite of the NEDD4 family [54] . More structural studies are needed in order to fully understand their mechanism of catalysis.
Close conformation in resting conditions ensures HECT inhibition
Precise control of E3s activity is required to ensure that their functions are restricted until activated. This restriction is fundamental to prevent excessive ubiquitination of substrates or misdirected autoubiquitination that may cause E3 instability. A pioneering work demonstrated that in the absence of bona fide substrates a subset of Nedd4-family E3 ligases are kept in a catalytically inactive state by intramolecular interaction between the N-terminal C2 domain and the C-terminal HECT domain [57] . A subsequent structural study revealed how the C2 induces a catalytically incompetent HECT domain conformation: by binding near the exosite of the HECT and possibly locking the catalytic cysteine far from the E2 binding site (Fig. 3A) , the C2 interferes with the Ub-thioester formation preventing conjugation of ubiquitin to the substrate [58] .
Recent exciting studies revealed that several inhibiting intramolecular interactions exist at least for this HECT class of enzymes. In 2006, data from Karin and colleagues suggested that ITCH is regulated by an intramolecular interaction between the central region of the protein (containing PRR and WW domains) and the HECT domain [59] . Further studies involved the WW domains of Nedd4-2 [60] and of ITCH and WWP2 [61] in the maintenance of the enzyme close conformation. A recent crystal structure of WWP2 finally provided the key element for this autoinhibition in the linker between the WW2 and the WW3 domains, called 2,3-linker [62] . This 26-residue alpha-helix is able to interact extensively with the N-lobe and the C-lobe of WWP2 HECT, maintaining the enzyme in a close conformation (Fig. 3B) . This regulatory module is functionally active in WWP1 and ITCH, which share sequence conservation in the same region [62, 63] . Interestingly, secondary structure prediction indicates that NEDD4 holds a similar alpha-helix C-terminal to the WW1 that may well be part of the inhibitory mechanism (as depicted in the model of Fig. 3A ), but this hypothesis awaits structural validation [62] .
In conclusion, the detailed inhibitory mechanism may vary across the various enzymes (for example, as a consequence of a different spacing between the domains) and thus needs to be studied at the single molecular level. The inhibitory conformations identified so far may easily coexist and synergize in the same HECT E3 to achieve full enzyme inhibition. Once again, HECTs of others subgroups are less studied: some of them are controlled by dimerization, as in the case of Huwe1 [56] or by oligomerization, as for E6AP [54] , a mechanism that may play a role also in the regulation of Rsp5 [64] . Notably, the RBRs (closely related to the HECTs) are also autoinhibited by subtly distinct mechanisms that tethers the RING2, also called Rcat, in an active state [10] .
Signalling-induced release of HECT inhibitory conformation
A critical issue that started to be addressed in the last years is how upstream signalling events may trigger the complete release of the C2 domain, leading to full ligase activation [65] . In a few cases, adaptor proteins may work as activators (Fig. 3C ). For example, by releasing C2-mediated autoinhibition, stimulating E2 binding and recruiting Smurf target, the adaptor protein Smad7 functions at multiple levels to control E3 activity and to ensure specificity in Smurf-catalysed ubiquitination [66] . In other cases, as for NEDD4 and NEDD4L, signalling is the driving force. It is wellestablished that calcium-mediated membrane translocation of the C2 relocalizes Nedd4/L, releasing the HECT activity [67, 68] (Fig. 3D ). Nedd4 activity is also modulated by tyrosine phosphorylation induced by receptor tyrosine kinases (RTKs), as demonstrated by Persaud et al. [19] (Fig. 3E) . The molecular requirements needed to activate the Nedd4 ligase upon EGFR and FGFR activation rely on a set of phosphorylation events occurring at the C2 and HECT domains mediated by the tyrosine kinase Src activated by the RTKs [19] . While a similar phosphorylationbased mechanism of regulation was demonstrated for Itch [59] , Chen et al. suggested that also for the 2-3 linker of WWP2 [62] (Fig. 3F) . Additional studies are needed to establish whether this could be a common way to activate also other HECT members. With few exceptions, other HECT E3 ligases have not been studied with regard to their inhibitory/activatory mechanisms. In vitro E6AP is a poorly active enzyme and it can be allosterically activated by another HECT E3, HERC2 [69] or by the HPV E6 oncoprotein [54] . On the contrary, binding of the tumour suppressor p14ARF to a specific central region of HUWE1 shifts its conformational equilibrium towards the inactive state [56] . Further molecular studies on these and other enzymes are anticipated since the identification of the ligase regulatory mechanisms is a key point for the development of therapeutics able to specifically modulate the desired HECT.
New advances towards HECT inhibitors and probes
The therapeutic potential of targeting the ubiquitin system was demonstrated by the approval by FDA of the reversible proteasome inhibitor Velcade (bortezomib) for the treatment of multiple myeloma [70, 71] . Better than the proteasome, E3 ligases appear to be promising targets for drug discovery as they represent the last step of the enzymatic cascade, capable of conferring a high degree of specificity and selectivity towards target substrates in cells. Up to now, only three FDA approved drugs target ubiquitin ligases: the teratogenic compound thalidomide and its analogues lenalidomide and pomalidomide whose primary target is the E3 ligase CRL4 [72] [73] [74] .
Inhibition of the catalytic activity of the HECT family could be achieved by attacking the catalytic cysteine residue, or by blocking the interaction between the ligase and the Ub-activated E2 or the substrate (Fig. 4) . To date, examples of small molecules targeting HECT E3 ligases in all these ways have been reported, including a general HECT inhibitor that targets the catalytically active cysteine [75] , another drug that seems to inhibit the transthiolation process [76] , and a NEDD4 inhibitor that binds the N-lobe exosite and inhibits processive ubiquitination [77] .
The Heclin (HECT ligase inhibitor) molecule was identified from a library of 17.500 compounds to selectively inhibit the activity of several components of the NEDD4 family in vitro and in vivo [75] . The small molecule does not interfere with E1 and E2 activity but instead causes a conformational change, which results in oxidation of the active site cysteine [75] . Using an ELISA-based high throughput screen (HTS), Rossi and co-workers demonstrated that clomipramine, an FDA approved drug clinically used as an antidepressant, has the ability to block ITCH self-ubiquitination and p73 ubiquitination [76] . In both cases, no structural information is available with regard to the inhibitors' binding site on the HECT molecule.
The first crystal structure of an HECT domain in complex with a small molecule was provided in 2015 [77] . In this study, the authors used an electrophilic fragment-based library capable of covalently reacting with the active cysteine to discover irreversible covalent inhibitors. Surprisingly, they found compounds that react with the noncatalytic cysteine in position 627 of the NEDD4 protein, and block the exosite binding, thus reducing the processivity of the enzymatic reaction [77] .
The last class of molecules identified as NEDD4 inhibitors are derivatives of indole-3-carbinol (I3C) [78, 79] . I3C is a natural phytochemical with antiproliferative effect on several biological processes. Isothermal titration calorimetry demonstrated that I3C directly binds to the purified HECT catalytic domain of NEDD4 [78] . Using the docking simulation protocol and thermal shift assay, Firestone and colleagues found that 1-benzyl-I3C derivatives may bind the NEDD4 N-lobe exosite and induce an antiproliferative effect on melanoma cells expressing oncogenic BRAF and wild-type PTEN [78, 79] . However, whether in vivo treatment with these derivatives would affect only NEDD4 activity remains to be tested.
Rather than blocking the enzyme activity a recent approach suggested the use of specific Ub variant (UbV) to modulate HECT catalysis [80] . The authors engineered a phage-displayed Ub library designed to randomize surface residues involved in interactions with the ubiquitin binding surface present in the enzymes of the ubiquitin cascade (E1, E2, E3s and DUBs) and in the Ub receptors. The screen of the Ub variants (UbVs) was performed against 19 of the 28 human HECT enzymes and lead to the identification of variants that are capable to selectively bind the Nlobe exosite and also, unexpectedly, the N-lobe surface involved in the interaction with the E2 [80] . No selective binders of the C-lobe Ub-binding site were found, indicating that the N-lobe is somehow preferred by these variants. As expected, the UbVs blocking the E2 binding site inhibited HECT activity by affecting the E2-HECT transthiolation process. Less clear is the interpretation of the UbVs binding in the N-lobe exosite that seem to exert opposite effects -inhibitory and activatory -on the different E3s tested. Several features may contribute to these disparate behaviours: i) not all the HECTs naturally possess a N-lobe exosite (e.g. E6AP); ii) some Ub variants can be used as Ub D and Ub A while others have the C-terminal glycines mutated and can only work as Ub A (e.g. NEDD4L UbVs); iii) along the same line, only some UbVs possess the critical lysine to function as Ub A (e.g. K63 in the case of NEDD4 family members); and iv) some UbVs show a strongly increased affinity while the binding improvement is minimal for others UbVs (as in the case of N4.4). To correctly interpret these data, a careful biochemical analysis of the single HECT with their specific UbVs is highly desirable. While lacking an obvious therapeutic potential, these variants are valuable tools to clarify the HECT mechanisms of catalysis. To this end, it will be interesting to solve the structures of the poorly characterized members together with their specific UbVs.
Conclusions and perspective
E3 ligases are the master regulators of the ubiquitination process. Progress has been made in the understanding of the structure-function aspects of these enzymes as well as in the identification and characterization of their substrates and regulators. Enzymatic mechanisms have remained remarkably elusive and started to be revealed only in the recent years. Much more remains to be done, and understanding how HECT E3s are able to generate selected Ub polyubiquitin chains is now a major challenge. Another growing interest in the field is on the identification of HECT inhibitors. It is clear that these E3s play an important role in sporadic and hereditary human diseases including cancer, cardiovascular and neurological disorders [5] . With the preclinical success of PROTAC, HyT and SERDs [81] , it is easy to envisage a time when E3 inhibitors will become a precious addition to our pharmaceutical armamentarium. In recent years, few compounds able to modulate NEDD4 activity were disclosed but their lack of potency and specificity has precluded their use in the clinic. Certainly, the identification of hotspot surfaces for drug inhibition (such as the N-lobe exosite) and probes (such as UbVs) paves the way for a better understanding of the regulatory mechanisms of HECT E3 ligases. Definition of the structural features governing such mechanisms would drive towards more potent, safe and selective inhibitors. 
